Patient advocacy groups are hailing a new court ruling that could significantly reduce pharmaceutical costs for some patients.
On September 29, the U.S. District Court for the District of Columbia struck down an administrative rule from the Trump era that allowed health insurers to not count drug manufacturers' copay assistance toward a patient's out-of-pocket costs. The rule was especially burdensome for those with chronic diseases that involve expensive drugs, resulting in more out-of-pocket costs for patients who received the copay assistance.
Complete your profile to continue reading and get FREE access to BenefitsPRO, part of your ALM digital membership.
Your access to unlimited BenefitsPRO content isn’t changing.
Once you are an ALM digital member, you’ll receive:
- Critical BenefitsPRO information including cutting edge post-reform success strategies, access to educational webcasts and videos, resources from industry leaders, and informative Newsletters.
- Exclusive discounts on ALM, BenefitsPRO magazine and BenefitsPRO.com events
- Access to other award-winning ALM websites including ThinkAdvisor.com and Law.com
Already have an account? Sign In
© 2024 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.
